|
10126
|
ETCTN
|
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
|
Adult CIRB - Early Phase Emphasis
|
|
10129
|
ETCTN
|
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors
|
Adult CIRB - Early Phase Emphasis
|
|
10130
|
ETCTN
|
A phase I study of single agent tazemetostat in subjects with advanced solid tumors and B-cell lymphomas with hepatic dysfunction
|
Adult CIRB - Early Phase Emphasis
|
|
10131
|
ETCTN
|
A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel
|
Adult CIRB - Early Phase Emphasis
|
|
10132
|
ETCTN
|
A Phase I Study of the Wee 1 kinase (Wee 1) inhibitor AZD1775 in combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
|
Adult CIRB - Early Phase Emphasis
|
|
10136
|
ETCTN
|
A Phase 2 Study Of AZD1775, A WEE1 Inhibitor, In Patients With CCNE1 Amplification
|
Adult CIRB - Early Phase Emphasis
|
|
10139
|
ETCTN
|
A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma
|
Adult CIRB - Early Phase Emphasis
|
|
10144
|
ETCTN
|
A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
|
Adult CIRB - Early Phase Emphasis
|
|
10145
|
ETCTN
|
Phase 1b Study Of Copanlisib In Combination With Nivolumab Or With Nivolumab And Iplimumab
|
Adult CIRB - Early Phase Emphasis
|
|
10146
|
ETCTN
|
Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer
|
Adult CIRB - Early Phase Emphasis
|